Edition:
United States

Stryker Corp (SYK.N)

SYK.N on New York Stock Exchange

174.50USD
21 Sep 2018
Change (% chg)

$1.01 (+0.58%)
Prev Close
$173.49
Open
$173.51
Day's High
$174.95
Day's Low
$173.51
Volume
2,021,664
Avg. Vol
333,106
52-wk High
$179.84
52-wk Low
$138.98

Latest Key Developments (Source: Significant Developments)

Invuity To Be Acquired By Stryker Corporation For $7.40 Per Share
Tuesday, 11 Sep 2018 08:00am EDT 

Sept 11 (Reuters) - Invuity Inc ::INVUITY ANNOUNCES DEFINITIVE AGREEMENT TO BE ACQUIRED BY STRYKER CORPORATION FOR $7.40 PER SHARE IN CASH.INVUITY INC - DEAL FOR TOTAL EQUITY VALUE OF APPROXIMATELY $190 MILLION..INVUITY INC - STRYKER CORPORATION INTENDS TO FUND TRANSACTION WITH CASH ON HAND.INVUITY INC - BOARD APPROVED ENTERING INTO AGREEMENT.INVUITY - UNIT OF STRYKER WILL COMMENCE TENDER OFFER TO BUY ALL OUTSTANDING SHARES OF INVUITY COMMON STOCK IN EXCHANGE FOR $7.40 PER SHARE IN CASH.INVUITY INC - BOARD APPROVED ENTERING INTO AGREEMENT AND RECOMMENDS THAT CO'S STOCKHOLDERS TENDER THEIR SHARES IN UPCOMING TENDER OFFER.INVUITY - UNDER TERMS, AFTER COMPLETION OF TENDER OFFER, UNIT OF STRYKER CORPORATION MAKING OFFER WILL MERGE WITH AND INTO CO.  Full Article

Stryker's Spine Division Receives FDA Clearance For 3D-Printed Tritanium Tl Curved Posterior Lumbar Cage
Wednesday, 7 Mar 2018 08:47am EST 

March 7 (Reuters) - Stryker Corp ::STRYKER'S SPINE DIVISION RECEIVES FDA CLEARANCE FOR 3D-PRINTED TRITANIUM TL CURVED POSTERIOR LUMBAR CAGE.STRYKER CORP - 3D-PRINTED TRITANIUM TL CURVED POSTERIOR LUMBAR CAGE WILL BE AVAILABLE TO SURGEONS IN Q2 2018.  Full Article

Reg-Stryker Corp Announces Pricing Of $600 Million Senior Notes Offering
Monday, 26 Feb 2018 05:11pm EST 

Feb 26 (Reuters) - Stryker Corp ::REG-STRYKER CORPORATION ANNOUNCES PRICING OF $600 MILLION SENIOR NOTES OFFERING.STRYKER CORP - ‍PRICED AN OFFERING TO SELL $600 MILLION OF SENIOR UNSECURED NOTES DUE 2028​.STRYKER CORP - ‍SENIOR NOTES BEING ISSUED WILL BEAR INTEREST AT 3.650% PER YEAR​.  Full Article

U.S. FDA Grants Premarket Clearance Of Trevo Clot Retrieval Device To Concentric Medical Inc
Thursday, 15 Feb 2018 12:11pm EST 

Feb 15 (Reuters) - U.S. Food and Drug Administration::U.S. FOOD AND DRUG ADMINISTRATION SAYS CLEARED USE OF TREVO CLOT RETRIEVAL DEVICE TO TREAT CERTAIN STROKE PATIENTS UP TO 24 HOURS AFTER SYMPTOM ONSET.U.S. FDA SAYS GRANTED PREMARKET CLEARANCE OF TREVO DEVICE TO CONCENTRIC MEDICAL INC.  Full Article

Stryker Says Holds 95 Pct In Vexim; Intends To File Public Buy-Out Offer
Wednesday, 14 Feb 2018 10:01am EST 

Feb 14 (Reuters) - STRYKER CORP ::STRYKER CROSSES THE 95% THRESHOLDS IN VEXIM AND ANNOUNCES ITS INTENTION TO FILE A PROPOSED PUBLIC BUY-OUT OFFER FOLLOWED BY A SQUEEZE-OUT FOR THE OUTSTANDING SHARES OF VEXIM.‍SQUEEZE-OUT IS EXPECTED TO OCCUR DURING Q2 2018.PRICE PER SHARE OF EUR 20.  Full Article

Stryker Declares $0.47 Per Share Quarterly Dividend
Wednesday, 7 Feb 2018 08:00am EST 

Feb 7 (Reuters) - Stryker Corp ::REG-STRYKER DECLARES A $0.47 PER SHARE QUARTERLY DIVIDEND.  Full Article

Stryker Reports Q4 Earnings Per Share $1.21
Tuesday, 30 Jan 2018 04:05pm EST 

Jan 30 (Reuters) - Stryker Corp ::REG-STRYKER REPORTS 2017 RESULTS AND 2018 OUTLOOK.Q4 ADJUSTED EARNINGS PER SHARE $1.96.Q4 LOSS PER SHARE $0.66.SEES Q1 ADJUSTED EARNINGS PER SHARE $1.57 TO $1.62.Q4 EARNINGS PER SHARE VIEW $1.95 -- THOMSON REUTERS I/B/E/S.EXPECT 2018 ORGANIC SALES GROWTH TO BE IN RANGE OF 6.0% TO 6.5%.Q1 EARNINGS PER SHARE VIEW $1.60 -- THOMSON REUTERS I/B/E/S.QTRLY ‍REPORTED NET EARNINGS INCLUDES CHARGES FOR IMPACT OF TAX CUTS AND JOBS ACT OF 2017 AMONG OTHERS​.QTRLY CONSOLIDATED NET SALES OF $3.5 BILLION, INCREASED 10.0% AS REPORTED.Q4 REVENUE VIEW $3.40 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

BRIEF-Vexim 2017 Sales Up 17 Pct To 21.6 Million Euros
Friday, 12 Jan 2018 12:01pm EST 

Refiles to add missing 4th bullet.:VEXIM: +17% GROWTH IN SALES IN 2017 UP TO €21.6 MILLION.‍2017 SALES RESULTS PERFORMS BELOW EXPECTATIONS OF MANAGEMENT WHICH ANTICIPATED AN ANNUAL GROWTH OF +30%​.‍PROFITABILITY TARGET FOR 2017 WILL NOT BE ACHIEVED.FY ‍FINANCIAL RESULT WILL BE ADVERSELY AFFECTED BY EUR 5 MLN EXCEPTIONAL EXPENSES, PART OF OPERATION WITH STRYKER​.  Full Article

Stryker Expects 2017 Adj Net Earnings Per Diluted Share To Be Toward High End Of Previous Range Of $6.45-$6.50​
Tuesday, 9 Jan 2018 08:15am EST 

Jan 9 (Reuters) - Stryker Corp ::STRYKER - EXPECT 2017 ADJUSTED NET EARNINGS PER DILUTED SHARE TO BE TOWARD HIGH END OF PREVIOUSLY ANNOUNCED RANGE OF $6.45 TO $6.50​.- EXPECT 2017 ADJUSTED NET EARNINGS PER DILUTED SHARE TO BE TOWARD HIGH END OF OUR PREVIOUSLY ANNOUNCED RANGE OF $6.45 TO $6.50​.- WITH RESPECT TO U.S. TAX REFORM, ANTICIPATE A MODEST HEADWIND FOR 2018.STRYKER - ‍FOREIGN CURRENCY EXCHANGE IMPACT ON NET SALES IN Q4 WAS POSITIVE OF ABOUT 1.2 PERCENT AND NOMINAL IN FULL YEAR​.REG-STRYKER PROVIDES 2017 PRELIMINARY NET SALES RESULTS.Q4 SALES $3.5 BILLION VERSUS I/B/E/S VIEW $3.39 BILLION.STRYKER SAYS PRELIMINARY ORTHOPAEDICS NET SALES OF $1.3 BILLION AS REPORTED IN Q4.- ‍PRELIMINARY DOMESTIC NET SALES OF $2.5 BILLION AND $9.1 BILLION INCREASED 9.3% AND 10.1% AS REPORTED IN Q4 AND FULL YEAR​.- ‍PRELIMINARY INTERNATIONAL NET SALES OF $1.0 BILLION AND $3.4 BILLION INCREASED 11.7% AND 9.4% AS REPORTED IN Q4 AND FULL YEAR​.Q4 REVENUE VIEW $3.39 BILLION -- THOMSON REUTERS I/B/E/S.FY2017 EARNINGS PER SHARE VIEW $6.47 -- THOMSON REUTERS I/B/E/S.  Full Article

Entellus Medical Says Deal May Require Co To Pay Stryker A Termination Fee Of $20.5 Mln
Thursday, 7 Dec 2017 08:50am EST 

Dec 7 (Reuters) - Entellus Medical Inc ::ENTELLUS MEDICAL SAYS DEAL PROVIDES CO MAY BE REQUIRED TO PAY STRYKER TERMINATION FEE OF $20.5 MILLION UNDER CERTAIN CIRCUMSTANCES - SEC FILING.  Full Article

Medical device maker Stryker to buy K2M Group for about $1.4 billion

Medical device maker Stryker Corp said on Thursday it will buy smaller rival K2M Group Holdings Inc for about $1.4 billion, adding K2M's fast-growing spinal implant technology to its business.